NBIXNeurocrine Biosciences, Inc.

Filing: 8-K (Items 2.02, 9.01) | Filed with the SEC on: November 2, 2026 | Price: $164.59 | Today's Change: +13.24%

---

What Happened

Neurocrine Biosciences filed an 8-K with the SEC on November 2, 2026, disclosing its Q3 FY2026 financial results under Item 2.02 (Results of Operations and Financial Condition). The company reported revenue of $2.055 billion for the quarter, alongside operating income of $408.2 million and net income of $324.9 million. Diluted earnings per share came in at $3.19, with basic EPS at $3.27, reflecting a quarter of substantial profitability at scale.

Why It Matters

The scale of Q3 FY2026 revenue — $2.055 billion — underscores that Neurocrine has firmly transitioned into large-cap commercial territory. The operating income of $408.2 million implies a meaningful operating margin, and net income of $324.9 million translates directly into strong cash generation capacity. The stock's sharp single-day move of +13.24% to $164.59 signals that the market received these results as a material positive surprise relative to prior expectations. For investors tracking near-term fundamentals, the combination of top-line scale, operating leverage, and bottom-line profitability points to a business delivering on the commercial promise of its core franchise.

Analysis

The headline numbers here are striking on their own terms. A quarterly revenue run-rate of $2.055 billion annualizes to over $8 billion — a threshold that, if sustained, would place Neurocrine among a select group of pure-play neuroscience companies with truly large-scale commercial operations. The operating-to-net income conversion (from $408.2M operating income to $324.9M net income) reflects typical below-the-line costs but remains efficient.

The +13.24% single-session price reaction is notable — such moves on earnings day typically indicate results that materially exceeded consensus expectations rather than an in-line print. Investors should watch whether management's forward commentary (attached as Exhibit 99 under Item 9.01) provides updated guidance that sustains or builds on this quarter's momentum.

Key things to monitor going forward:

• Revenue trajectory: Whether the $2.055B quarterly figure represents a new baseline or was influenced by one-time factors (e.g., inventory build, milestone recognition).
• Operating leverage sustainability: The $408.2M operating income figure will be worth tracking against any expected increases in R&D or SG&A as the pipeline advances.
• EPS durability: Diluted EPS of $3.19 on a $324.9M net income base implies a diluted share count of roughly 102 million shares — any changes to buyback activity or dilution from equity compensation are worth watching.

The magnitude of this quarter's results and the market's reaction together make this one of the more significant earnings prints Neurocrine has reported, and the disclosed figures warrant close attention from anyone following the neuroscience and specialty pharma space.

---

Disclaimer

This report is a news and informational summary of a publicly filed SEC disclosure. It does not constitute investment advice, an offer to buy or sell any security, or an equity research recommendation of any kind. No rating or price target is issued or implied. Investors should conduct their own due diligence and consult a qualified financial adviser before making any investment decisions.

Source

Filed with the SEC on 2026-11-02. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/914475/000091447526000053/nbix-20261102.htm